Jones, Stephen K. Jr http://orcid.org/0000-0001-8387-1917
Hawkins, John A. http://orcid.org/0000-0002-2943-9397
Johnson, Nicole V. http://orcid.org/0000-0003-4351-125X
Jung, Cheulhee
Hu, Kuang http://orcid.org/0000-0003-2933-4824
Rybarski, James R. http://orcid.org/0000-0001-9960-1161
Chen, Janice S.
Doudna, Jennifer A. http://orcid.org/0000-0001-9161-999X
Press, William H. http://orcid.org/0000-0003-0771-0841
Finkelstein, Ilya J. http://orcid.org/0000-0002-9371-2431
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (F32AG053051)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R01GM124141)
Welch Foundation (F-1808)
Univesity of Texas at Austin, College of Natural Sciences Catalyst Award
Article History
Received: 15 July 2019
Accepted: 14 July 2020
First Online: 7 September 2020
Competing interests
: The authors declare competing financial interests. The authors have filed patent applications on the CHAMP platform. The Regents of the University of California have patents issued and pending for CRISPR technologies on which J.A.D. is an inventor. J.A.D. is a co-founder of Caribou Biosciences, Editas Medicine, Intellia Therapeutics, Scribe Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member of Caribou Biosciences, Intellia Therapeutics, eFFECTOR Therapeutics, Scribe Therapeutics, Synthego, Mammoth Biosciences and Inari. J.A.D. is a member of the board of directors at Driver and Johnson & Johnson and has sponsored research projects by Roche Biopharma and Biogen. J.A.C. is a co-founder of Mammoth Biosciences. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The authors declare no competing non-financial interests.